



RECEIVED

APR 30 2002

TC 1700

002 PATENT 479 P

TECH CENTER 1600/2900

MAY 01 2002

RECEIVED

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Kyogo ITOH et al. CONF.: 2449
SERIAL NO: 09/720,469 GROUP: 1642
FILED: December 22, 2000 EXAMINER: N. DAVIS
FOR: TUMOR ANTIGEN PEPTIDES DERIVED FROM CYCLOPHILIN B

RESPONSE TO RESTRICTION REQUIREMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

April 29, 2002
(Monday)

Sir:

In Response to the Restriction Requirement dated March 27, 2002, the due date for response being Monday, April 29, 2002, the following remarks are respectfully submitted.

R E M A R K S

Claims 1-25 are pending in the present application. No new matter is inserted into the application.

Restriction Requirement

In response to the Restriction Requirement, Applicants elect Group A, claims 1-14 and 25, drawn to a tumor antigen peptide derived from cyclophilin, a pharmaceutical composition, and a diagnostic agent, with traverse. Reconsideration and withdrawal of the Restriction Requirement are respectfully requested.